logo-loader

Avivagen commercializing its OxC-beta livestock product around the world

Published: 11:07 19 Jul 2019 EDT

Avivagen Inc (TSXV:VIV) CEO Kym Anthony tells Proactive Investors the Canadian life sciences company has developed and begun commercializing its OxC-beta Livestock product that promotes immune functions in livestock in the the Philippines, Taiwan, New Zealand and Thailand.

Anthony says the product, which has been shown to be effective in replacing the antibiotics added to livestock feeds, will soon be entering the US market.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 11 minutes ago